Assured Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Assured Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,151	Closed	-$2.97M	–	835
2019 Q1	$2.97M	Sell	16,151 -12,864	-44%	-$2.38M	0.03%	228
2018 Q4	$4.81M	Buy	29,015 +1,274	+5%	+$221K	0.14%	189
2018 Q3	$5.35M	Sell	27,741 -15,141	-35%	-$2.7M	0.1%	241
2018 Q2	$7.29M	Sell	42,882 -9,094	-17%	-$1.41M	0.14%	152
2018 Q1	$8.47M	Sell	51,976 -37,281	-42%	-$6.09M	0.19%	127
2017 Q4	$13.4M	Buy	89,257 +25,182	+39%	+$3.73M	0.27%	68
2017 Q3	$9.74M	Buy	64,075 +32,399	+102%	+$4.88M	0.2%	91
2017 Q2	$4.08M	Buy	31,676 +26,424	+503%	+$3.18M	0.08%	146
2017 Q1	$574K	Buy	+5,252	New	+$462K	0.01%	406
2016 Q2	–	Sell	-1,867	Closed	-$148K	–	687
2016 Q1	$148K	Buy	1,867 +764	+69%	+$69.1K	﹤0.01%	505
2015 Q4	$139K	Buy	+1,103	New	+$133K	﹤0.01%	516

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Assured Investment Management's VRTX Position: Q2 2019 in Review

Assured Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 16,151 shares — an estimated $2.97M sold.

Assured Investment Management first reported a position in VRTX in Q4 2015 and held it in 11 quarters. The position peaked at $13.4M in Q4 2017. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Assured Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Assured Investment Management sold 16,151 Vertex Pharmaceuticals shares in Q2 2019, an estimated $2.97M.
Assured Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 11 quarters.
Assured Investment Management's Vertex Pharmaceuticals position peaked at $13.4M in Q4 2017.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.